Published in J Theor Biol on March 25, 2014
A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature (2015) 1.66
HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma. Mol Cancer (2014) 1.02
The mathematics of cancer: integrating quantitative models. Nat Rev Cancer (2015) 1.00
Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLoS Comput Biol (2015) 0.96
Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc Natl Acad Sci U S A (2014) 0.94
Surviving apoptosis: life-death signaling in single cells. Trends Cell Biol (2015) 0.90
Evolutionary rescue: linking theory for conservation and medicine. Evol Appl (2014) 0.89
Differences in predictions of ODE models of tumor growth: a cautionary example. BMC Cancer (2016) 0.88
Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates. Sci Rep (2016) 0.83
Polyphyllin I (PPI) increased the sensitivity of hepatocellular carcinoma HepG2 cells to chemotherapy. Int J Clin Exp Med (2015) 0.80
Emerging targets for glioblastoma stem cell therapy. J Biomed Res (2015) 0.79
How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient. PLoS Biol (2017) 0.79
Modeling drug resistance in a conjoint normal-tumor setting. Theor Biol Med Model (2015) 0.78
Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination. Oncotarget (2016) 0.77
Pharmacokinetics and drug-interactions determine optimum combination strategies in computational models of cancer evolution. Cancer Res (2017) 0.77
Learning about the Importance of Mutation Prevention from Curable Cancers and Benign Tumors. J Cancer (2016) 0.76
Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases. Math Biosci Eng (2016) 0.76
Cell death in genome evolution. Semin Cell Dev Biol (2015) 0.75
Universal Asymptotic Clone Size Distribution for General Population Growth. Bull Math Biol (2016) 0.75
4th international conference on tumor progression and therapeutic resistance: meeting report. Cancer Biol Ther (2015) 0.75
The evolution of tumour phylogenetics: principles and practice. Nat Rev Genet (2017) 0.75
Controlling the Master: Chromatin Dynamics at the MYC Promoter Integrate Developmental Signaling. Genes (Basel) (2017) 0.75
Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. PLoS Comput Biol (2016) 0.75
Resistance to Cell Death and Its Modulation in Cancer Stem Cells. Crit Rev Oncog (2016) 0.75
Modeling Tumor Clonal Evolution for Drug Combinations Design. Trends Cancer (2016) 0.75
Modeling multi-mutation and drug resistance: analysis of some case studies. Theor Biol Med Model (2017) 0.75
Resistance Development: A Major Piece in the Jigsaw Puzzle of Tumor Size Modeling. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
Chemosensitivity of anaplastic thyroid cancer based on a histoculture drug response assay. Int J Endocrinol (2015) 0.75
HMGB1-mediated autophagy decreases sensitivity to oxymatrine in SW982 human synovial sarcoma cells. Sci Rep (2016) 0.75
Microenvironmental Niches and Sanctuaries: A Route to Acquired Resistance. Adv Exp Med Biol (2016) 0.75
Towards a better cancer precision medicine: systems biology meets immunotherapy. Curr Opin Syst Biol (2017) 0.75
PKPD modeling of acquired resistance to anti-cancer drug treatment. J Pharmacokinet Pharmacodyn (2017) 0.75
Mutations of Bacteria from Virus Sensitivity to Virus Resistance. Genetics (1943) 165.64
Stochastic gene expression in a single cell. Science (2002) 34.54
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Stochasticity in gene expression: from theories to phenotypes. Nat Rev Genet (2005) 14.39
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 12.02
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
The distribution of the numbers of mutants in bacterial populations. J Genet (1949) 8.79
Mechanisms of cancer drug resistance. Annu Rev Med (2002) 7.91
Targeted cancer therapy. Nature (2004) 7.81
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell (2006) 4.07
The distribution of fitness effects among beneficial mutations. Genetics (2003) 3.97
On fluctuation analysis: a new, simple and efficient method for computing the expected number of mutants. Genetica (1992) 3.54
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med (2001) 3.45
Variability and robustness in T cell activation from regulated heterogeneity in protein levels. Science (2008) 3.38
Fluctuation analysis: the probability distribution of the number of mutants under different conditions. Genetics (1990) 3.32
Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A (2005) 3.03
Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med (1948) 2.81
HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res (2006) 2.74
Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol (2009) 2.40
Evolution of resistance during clonal expansion. Genetics (2006) 2.36
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res (2001) 2.29
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A (2006) 2.13
Evolution of resistance and progression to disease during clonal expansion of cancer. Theor Popul Biol (2009) 1.97
The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res (1984) 1.92
Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep (1977) 1.82
A generalized Luria-Delbrück model. Math Biosci (2005) 1.72
Progress of a half century in the study of the Luria-Delbrück distribution. Math Biosci (2000) 1.72
A theoretical quantitative model for evolution of cancer chemotherapy resistance. Biol Direct (2010) 1.69
Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med (1958) 1.66
The initial clinical trial of nitrogen mustard. Am J Surg (1963) 1.54
Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J (2001) 1.53
The evolution of two mutations during clonal expansion. Genetics (2007) 1.52
A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull Math Biol (1986) 1.45
Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol (2009) 1.43
Growth of nonnecrotic tumors in the presence and absence of inhibitors. Math Biosci (1995) 1.40
Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res (1986) 1.38
Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology (2003) 1.38
Evolutionary dynamics of escape from biomedical intervention. Proc Biol Sci (2003) 1.38
Stochastic modeling of drug resistance in cancer. J Theor Biol (2005) 1.35
Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc (1946) 1.33
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica (2007) 1.29
Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol Biomarkers Prev (2004) 1.22
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thorac Oncol (2012) 1.22
Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia. PLoS One (2009) 1.20
Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res (2001) 1.19
Effect of cellular quiescence on the success of targeted CML therapy. PLoS One (2007) 1.18
Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol (2003) 1.16
Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep (1983) 1.16
Evolution of resistance to anti-cancer therapy during general dosing schedules. J Theor Biol (2009) 1.15
A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. Math Biosci (2000) 1.14
Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm (2011) 1.10
An explicit representation of the Luria-Delbrück distribution. J Math Biol (2001) 1.09
Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol Cancer Ther (2003) 1.08
Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst (1977) 1.07
Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front Oncol (2013) 1.05
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ. Neuro Oncol (2013) 1.05
Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol (1997) 1.03
A mathematical model of periodically pulsed chemotherapy: tumor recurrence and metastasis in a competitive environment. Bull Math Biol (1996) 1.01
The fixed-size Luria-Delbruck model with a nonzero death rate. Math Biosci (2007) 1.01
The worst drug rule revisited: mathematical modeling of cyclic cancer treatments. Bull Math Biol (2010) 1.01
Somatic mosaicism and cancer: inference based on a conditional Luria-Delbrück distribution. J Theor Biol (2003) 1.00
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol (2010) 0.99
Optimal control for a stochastic model of cancer chemotherapy. Math Biosci (2000) 0.99
Quantitative models of nuclear transport. Curr Opin Cell Biol (2005) 0.99
Cell motility and drug gradients in the emergence of resistance to chemotherapy. Proc Natl Acad Sci U S A (2013) 0.99
Tumor growth dynamics: insights into evolutionary processes. Trends Ecol Evol (2013) 0.95
Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. Theor Popul Biol (2007) 0.91
Stochastic analysis of intermediate lesions in carcinogenesis experiments. Risk Anal (1991) 0.91
Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal (2006) 0.91
A mathematical model of the development of drug resistance to cancer chemotherapy. Eur J Cancer Clin Oncol (1987) 0.90
The dynamics of gene amplification described as a multitype compartmental model and as a branching process. Math Biosci (1991) 0.90
Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency. Cancer Chemother Pharmacol (1992) 0.89
Drug kinetics and drug resistance in optimal chemotherapy. Math Biosci (1995) 0.88
On the role of endothelial progenitor cells in tumor neovascularization. J Theor Biol (2005) 0.86
Ponatinib for chronic myeloid leukemia. N Engl J Med (2012) 0.86
Dosage parameters in chemotherapy of breast cancer. Breast Dis (2001) 0.86
On the probability of random genetic mutations for various types of tumor growth. Bull Math Biol (2012) 0.84
High-dose chemotherapy in breast cancer. Drugs (2004) 0.82
Modelling chemotherapy resistance in palliation and failed cure. J Theor Biol (2008) 0.82
The forty-year-old mutation theory of Luria and Delbrück and its pertinence to cancer chemotherapy. Adv Cancer Res (1983) 0.80
The effect of heterogeneity on optimal regimens in cancer chemotherapy. Math Biosci (2003) 0.79
Optimal chemical control of populations developing drug resistance. IMA J Math Appl Med Biol (1992) 0.79
Accumulation of neutral mutations in growing cell colonies with competition. J Theor Biol (2012) 0.79
Optimal control of tumor size used to maximize survival time when cells are resistant to chemotherapy. Math Biosci (1992) 0.78
On Bartlett's formulation of the Luria-Delbrück mutation model. Math Biosci (2008) 0.76